Biogen
BIIB
927 hedge funds and large institutions have $24.8B invested in Biogen in 2022 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 297 increasing their positions, 354 reducing their positions, and 94 closing their positions.
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
0.67% less ownership
Funds ownership: 83.82% → 83.15% (-0.67%)
4% less capital invested
Capital invested by funds: $25.9B → $24.8B (-$1.07B)
5% less call options, than puts
Call options by funds: $974M | Put options by funds: $1.03B
3% less funds holding
Funds holding: 952 → 927 (-25)
16% less repeat investments, than reductions
Existing positions increased: 297 | Existing positions reduced: 354
17% less first-time investments, than exits
New positions opened: 78 | Existing positions closed: 94
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$130M |
| 2 |
Renaissance Technologies
New York
|
+$103M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$89.7M |
| 4 |
Morgan Stanley
New York
|
+$86.1M |
| 5 |
D.E. Shaw & Co
New York
|
+$74M |
Top Sellers
| 1 |
SAM
Southeastern Asset Management
Memphis,
Tennessee
|
-$178M |
| 2 |
Man Group
London,
United Kingdom
|
-$168M |
| 3 |
ClearBridge Investments
New York
|
-$111M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$92.3M |
| 5 |
Two Sigma Investments
New York
|
-$85.6M |
BIIB Hedge Fund Activity: Q2 2022 in Review
927 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2022, worth a combined $24.8B — down 4.1% from $25.9B a quarter earlier.
Sellers outnumbered buyers: 94 funds closed out of BIIB and 78 opened new positions — a net loss of 16 holders — while 354 trimmed existing stakes and 297 added.
The largest buyer was Fidelity Investments, adding an estimated $130M. The largest seller was Southeastern Asset Management, exiting entirely with an estimated $178M sold.
- 927 institutional investors held Biogen (BIIB) as of Q2 2022, down from 952 in Q1 2022.
- Funds reported $24.8B of Biogen stock for Q2 2022, down 4.1% quarter-over-quarter.
- 78 funds opened new Biogen positions in Q2 2022 and 94 closed out, a net change of -16 holders.
- The largest Biogen buyer in Q2 2022 was Fidelity Investments, an estimated $130M added.
- The largest Biogen seller in Q2 2022 was Southeastern Asset Management, an estimated $178M sold.
Based on aggregated 13F filings for Q2 2022.